Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 10/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | STAT5B | P51692 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7467733 | 0.90 | CYP19A1 (0.44) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL3286247 | 0.87 | KEAP1 (0.43) | KEAP1NFE2L2F2 | |
| SCHEMBL8817183 | 0.86 | NQO2 (0.40) | KEAP1NFE2L2MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL5681907 | 0.85 | HPGD (0.39) | SMN1; SMN2L3MBTL1F2CYP19A1EGFR | |
| SCHEMBL5203170 | 0.84 | NPC1 (0.38) | SMN1; SMN2L3MBTL1CYP19A1EGFR | |
| SCHEMBL5314203 | 0.83 | KEAP1 (0.39) | KEAP1NFE2L2L3MBTL1NPSR1F2 | |
| SCHEMBL5264076 | 0.82 | KEAP1 (0.40) | KEAP1NFE2L2F2 | |
| SCHEMBL3289538 | 0.82 | KEAP1 (0.40) | KEAP1NFE2L2F2 | |
| SCHEMBL8818386 | 0.81 | ESR1 (0.39) | F2STAT5B | |
| SCHEMBL5206971 | 0.78 | CYP19A1 (0.47) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718646-B2 | Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20080261949-A1 | ethyl 4-[4-(2-hydroxy-3-(4-hydroxy-3-(methylsulphonylamino)phenoxy)propylamino)cyclohexyl]benzoic acid; beta-3 adrenergic receptor agonist; tocolytics; delaying preterm birth; antidiabetic; obesity; oxyalkylation of the phenyl(alkyl)cyclohexyl(alkyl)amine with a glycidyl ether | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-7419974-B2 | Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-09-02 | — | — | US | disclosed |
| US-7388031-B2 | Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-06-17 | — | — | US | disclosed |
| EP-1341753-B1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-09-26 | — | — | EP | disclosed |
| CN-1935787-A | Cyclohexyl (alkyl) -propanolamines, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2007-03-28 | — | — | CN | disclosed |
| US-20070015745-A1 | Cyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | US | disclosed |
| CN-1283622-C | Cyclohexyl (alkyl) -propanolamines, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2006-11-08 | — | — | CN | disclosed |
| US-20040053916-A1 | Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | SANOFI (FR) | 2004-03-18 | — | — | US | disclosed |
| CN-1478074-A | Cyclohexyl (alkyl) -propanolamines, process for their preparation and pharmaceutical compositions containing them | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-02-25 | — | — | CN | disclosed |
| EP-1341753-A1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002044139-A1 | CYCLOHEXYL(ALKYL)-PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-06-06 | — | — | WO | disclosed |
| WO-1997034905-A1 | PHOSPHORUS CONTAINING ARYLOXY AND ARYLTHIOPROPANOL AMINE DERIVATIVES USEFUL AS BETA ADRENORECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261949-A1 | ethyl 4-[4-(2-hydroxy-3-(4-hydroxy-3-(methylsulphonylamino)phenoxy)propylamino)cyclohexyl]benzoic acid; beta-3 adrenergic receptor agonist; tocolytics; delaying preterm birth; antidiabetic; obesity; oxyalkylation of the phenyl(alkyl)cyclohexyl(alkyl)amine with a glycidyl ether | ADRB3, FFAR3, ADRB2 | KEAP1 3522/4885NFE2L2 1005/4885MAPT 4694/4885 |
| US-20070015745-A1 | Cyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same | C5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | KEAP1 2983/4885NFE2L2 1778/4885MAPT 3345/4885 |
| US-20040053916-A1 | Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADRA2C, ADRA1A | KEAP1 3432/4885NFE2L2 1861/4885MAPT 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.